Drugs / JMKX003002
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05907382 | May → Dec 2023 | — | Jemincare | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06664125 | Dec 2024 → Jun 2025 overdue | hyperphosphatemia | Jemincare | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX003002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05907382 ↗ |
| Route | Oral | “administered orally” NCT05907382 ↗ |